Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Prospects for specific influenza treatment

Odnovorov A., Garaev T., Grebennikova T., Pleteneva T.
Systematic Reviews in Pharmacy
Vol.11, Issue2, P. 242-248
Опубликовано: 2020
Тип ресурса: Статья

DOI:10.5530/srp.2020.2.37

Аннотация:
Influenza is an acute respiratory disease caused by the flu virus. The influenza virus is a RNA-containing virus that causes mass epidemics and pandemics. There are currently many ways in which influenza can be specifically prevented and treated. Specific influenza prevention includes vaccination. However, the antigenic variability of the virus reduces the effectiveness of the vaccine. Specific therapy for influenza infection includes several classes of drugs, among them neuraminidase (NA) inhibitors - oseltamivir, zanamivir, and M2-protein inhibitors - amantadine, rimantadine. The widespread use of these drugs and the high variability of the influenza virus lead to a gradual loss of their pharmacological effect. Among the new developments of antiviral drugs, we should mention histidyl-1-adamantyl ethylamine, which is a modification of the molecule of Rimantadine and at the stage of preclinical studies showed sufficient antiviral activity. A representative of another class of drugs - a
Ключевые слова:
Antiviral activity; Baloxavir marboxyl; Favipiravir; Influenza virus; Neuraminidase inhibitors; Rimantadine derivatives
amantadine; baloxavir marboxil; favipiravir; influenza vaccine; oseltamivir; rimantadine; sialidase inhibitor; zanamivir; antiviral activity; Article; drug effect; drug safety; human; influenza; influenza vaccination; Influenza virus; priority journal; public health problem; virus envelope
Язык текста: Английский
ISSN: 0976-2779
Odnovorov A.
Garaev T.
Grebennikova T.
Pleteneva T.
Одноворов А.
Гараев Т.
Гребенникова Т.
Плетенева Т.
Prospects for specific influenza treatment
Текст визуальный непосредственный
Systematic Reviews in Pharmacy
Vol.11, Issue2 P. 242-248
2020
Статья
Antiviral activity Baloxavir marboxyl Favipiravir Influenza virus Neuraminidase inhibitors Rimantadine derivatives
amantadine baloxavir marboxil favipiravir influenza vaccine oseltamivir rimantadine sialidase inhibitor zanamivir antiviral activity Article drug effect drug safety human influenza influenza vaccination Influenza virus priority journal public health problem virus envelope
Influenza is an acute respiratory disease caused by the flu virus. The influenza virus is a RNA-containing virus that causes mass epidemics and pandemics. There are currently many ways in which influenza can be specifically prevented and treated. Specific influenza prevention includes vaccination. However, the antigenic variability of the virus reduces the effectiveness of the vaccine. Specific therapy for influenza infection includes several classes of drugs, among them neuraminidase (NA) inhibitors - oseltamivir, zanamivir, and M2-protein inhibitors - amantadine, rimantadine. The widespread use of these drugs and the high variability of the influenza virus lead to a gradual loss of their pharmacological effect. Among the new developments of antiviral drugs, we should mention histidyl-1-adamantyl ethylamine, which is a modification of the molecule of Rimantadine and at the stage of preclinical studies showed sufficient antiviral activity. A representative of another class of drugs - a